Clinical-stage drug development company, Evgen Pharma, has been granted a key European patent ascribing intellectual property rights to the company for a method of stabilising sulforaphane, the naturally occurring compound which is the basis of its lead product, SFX-01.
Patent
This core patent, which is set to expire on 23 January 2028, is the company’s second process patent grant in Europe and follows on from its announcement in October last year (2017) about its manufacturing and scale-up grant. Composition-of-matter and manufacturing patents have already been granted in the USA. Patents are also granted, or in the process towards being granted, in other key commercial territories.
“We are delighted by the grant of this core patent in Europe, which further expands our intellectual property position and complements similar grants in the USA, Canada and Australia,” said Steve Franklin, CEO of Evgen Pharma. “This patent grant is timely from a commercial perspective as we are moving close to the announcement of our first Phase II clinical data from SFX-01, which we continue to expect in the first half of this year as part of our ongoing STEM trial in breast cancer.”